Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

OBJ LIMITED19/05/200415/09/2020

Shareholder links

Our website ranking of OBJ: rating 3
(3 out of 5)



Automic Group
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000OBJ3
Address: Level 1, 284 Oxford Street, LEEDERVILLE, WA, AUSTRALIA, 6007
Tel:  08 9443 3011Fax: 08 9443 3866

Date first listed: 29/05/2000
Company Secretary: Mr John J Palermo
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Drug delivery technology company that specialises in transdermal drug delivery technologies

News & Events

Expand this box to read and print

name changed to Wellfully Limited


The suspension of trading in the securities of OBJ Limited will be lifted immediately following the release by OBJ of an operations update and completion of a capital raising


OBJ recently announced the launch of its RÉDUIT skincare range. The RÉDUIT One and Hairpods range has been rolled out with a focus on both the retail and professional haircare markets. The company's device technology business is expecting to announce new product launches in the field of surface hygiene, in addition to beauty technology. OBJ continues to progress toward an anticipate UK and Australia launch of Bodyguard patches during early 2021. OBJ continues to work closely with P&G under the master licensing agreement between the 2 companies. OBJ's R&D team continues to research on applications for the company's Magnetic Misting technologies, beyond the current beauty and hygiene focus. OBJ completed a pro-rata non-renounceable entitlement offer, followed by a placement, together raising up to approximately $4.56 million before costs.


The company releases an Appendix 2A - Oversubscriptions.


The company releases an Appendix 2A - Placement and Shortfall.


OBJ has accepted oversubscriptions for the placement of a further 635,351 fully paid ordinary shares at A$0.10 per share to raise approximately a further $63,535 before costs.


The company releases an Appendix 2A.


The company releases a notice of Proposed issue of Securities - OBJ.


The company releases the Results of General Meeting.


The company launches RÉDUIT's skincare range. RÉDUIT is OBJ's technology brand established in Neuchâtel, Switzerland, specifically to commercialise OBJ's enhanced drug delivery technologies in the luxury beauty space.


The company releases an Appendix 2A.


The company releases a Presentation for August 2020.


The company has successfully completed its non-renounceable pro-rata entitlement offer to raise up to $3,016,000 before costs. Shareholders were offered one (1) new share for every three (3) shares held at the record date, at an issue price of $0.10 per share. OBJ received acceptances for 11,220,018 new shares, raising approximately $1,122,002. This represented 37% of all new shares offered and leaves a shortfall of 18,939,482 new shares.


The company lodges its Quarterly Report for the period ended 30 June 2020.


The company lodges an Appendix 4C June 2020.


The prospectus and entitlement and acceptance form for the non-renounceable pro-rata entitlement offer will today be despatched to eligible shareholders, and notifications will also be sent to ineligible shareholders.


An EGM will be held at the offices of RSM Perth at the Sir Cyril Bird Boardroom, Level 32 Exchange Tower, 2 The Esplanade, Perth Western Australia on 19 August 2020 commencing at 11.00am (Perth time). Proxy forms must be received by the Company's share registry Automic by 11:00am (Perth time) on Monday, 17 August 2020.


The company releases a notice of Proposed issue of Securities - OBJ.


The company issues a prospectus for a non-renounceable pro rata entitlement issue of one (1) New Share for every three (3) Shares held by Eligible shareholders at the Record Date at an issue price of $0.10 (10 cents) per New Share to raise up to approximately $3,016,000 before costs.


The company announces a proposed pro-rata non-renounceable entitlement offer, to be followed by a proposed placement, together raising up to approximately $4.5 million before costs. The proceeds are intended to be used for technology licensing, business development, BodyGuard go-to-market activities, device division development and go-to-market activities, and redemption of the convertible notes, as well as providing for general working capital.


Various subsidiaries were established to form OBJ's Wellfully device business. The company agreed to acquire some of the subsidiaries from Mr. Paul Peros. The consideration was agreed to be $120,000 worth of ordinary shares in the company at a price per share equivalent to the 30-day volume weighted average price of the company's shares immediately prior to closing of the transaction. By mutual agreement with Mr. Peros, the payment of the consideration has been delayed and these shares are yet to be issued. These shares are anticipated to be issued before the end of this calendar year.


The company launches its first wholly-owned consumer brand, RÉDUIT. The new RÉDUIT range is based on OBJ's proprietary Magnetic Misting technologies. Initial focus will be on hair-care and hair-styling solutions.


The company lodges its Shareholder Update March 2020.


The company lodges its Appendix 4C March 2020.


The company releases a notice of Proposed issue of Securities - OBJ.


The company has secured loan facilities for up to $2.3 million via the issue of convertible notes.


The company and Mr Danny Pavlovich, the sole shareholder of Export Corporation (Australia) Pty Ltd, have agreed to terminate the share sale agreement between the parties pursuant to which OBJ proposed to acquire all of the issued share capital in Nutrition Systems.


The company lodges its Appendix 4D 31 December 2019.


we understand that on or about this date the company consolidated its shares 1 for 20


The company releases the results of its General Meeting.


The company releases an Investor Presentation.


Since signing the share sale agreement, the parties, together with their legal and corporate advisors, have been working diligently to satisfy the conditions for completion of the acquisition. The company is progressing preparation of the prospectus for the capital raising, which is a key condition to completion. The parties have also agreed to extend the end date for satisfaction of the conditions precedent to completion of the acquisition to 4 May 2020. The indicative timeable remains the same.


The company releases a notification of consolidation of its securities. Shareholders get 1 share for every 20 presently owned.


The company releases its Shareholder Update December 2019 Quarter.


The company lodges its Appendix 4C December 2019 Quarter.


OBJ has entered into a share sale agreement to acquire Export Corporation, the owner of Nutrition Systems, for $85 million comprising $50 million in cash and $35 million in equity. The notice of meeting relating to the proposed acquisition has today been issued. OBJ Shareholders are now able to vote on each of the resolutions via Proxy Form provided in the NoM. Nutrition Systems is a highly profitable distributor and wholesaler of nutritional wellness products in Australia and New Zealand "“ focusing on highest quality sports nutrition products from the USA. Acquisition will change the nature of the Company's main activities from a pharmaceuticals, biotechnology and life sciences company to a vertically integrated, science-based wellness company. Benefits of the acquisition of Nutrition Systems to OBJ shareholders include: complementing the company's existing operations in line with the Board's strategy to strengthen the company's trading aspect within the health and wellness space; will bring OBJ closer to its target markets and the consumer; and will add value to the company for the benefit of all shareholders. OBJ proposes to change the company's name to Wellfully Limited. Nutrition Systems CEO and former elite athlete Danny Pavlovich will join the OBJ Board once the acquisition is settled and hold over 20% stake in OBJ. Global wellness industry is a highly lucrative market that has been enjoying a high growth trajectory in recent years (12.8% growth from 2015 "“ 2017). The meeting will be held at 10:00 am on 18 February 2020 at RSM Perth Sir Cyril Bird Boardroom Level 32, Exchange Tower 2 The Esplanade Perth WA 6000.


The company has executed two new licensing agreements with P&G, a third addendum and release under the product development agreement of April 2016, and a first amendment to five licensing term sheets under the master licensing agreement of August 2016. The agreements are designed to harmonise and unify a number of separate agreements already in existence between the two companies and improve the practical aspects of their operation. Highlights for OBJ include: improved royalty rates; revised: payment schedules and exclusivities and distribution routes for existing OBJ products and technologies; more clearly defined exclusivity provisions; and the release back to OBJ of all beauty sub-categories other than skin care.


The company releases the results of its 2019 AGM.


The company releases its AGM Presentation.


The Australian Patent Office has issued a Notice of Acceptance for Bodyguard Patent No. 2015274237, covering the range of Bodyguard products. The company was notified of the patent being accepted on 14th November 2019 with an expiry date of 10th June 2035, and will now move to grant upon the payment and processing of normal fees. There are no further obstacles to overcome. The company awaits responses to the same patent application filed in USA, Europe, China and Hong Kong.


The securities of OBJ Limited will be suspended from quotation immediately, at the request of OBJ, following the announcement that it has entered into an agreement proposing to acquire Export Corporation (Australia) Pty Ltd. OBJ's securities will remain suspended until ASX is satisfied that all relevant information required under Guidance Note 12: Change to Activities has been announced to the market. ASX has also exercised its discretions under Listing Rule 11.1.2 to require the Proposed Acquisition to be conditional on approval by OBJ's ordinary security holders and under Listing Rule 11.1.3 to require OBJ to recomply with Chapters 1 and 2 of the Listing Rules. If ASX is satisfied that OBJ has provided sufficient information to enable its securitiesto be reinstated and security holders approve the Proposed Acquisition, it is expected that OBJ's securities will again be suspended from quotation immediately following such security holder approval and will remain suspended until OBJ has recomplied with Chapters 1 and 2 of the Listing Rules.


The securities of OBJ Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of OBJ, pending the release of an announcement.


The suspension of trading in the securities of OBJ Limited will be lifted immediately following the receipt of an announcement.


has signed a new agreement with Procter & Gamble for the exclusive rights to another of OBJ's technology platforms. The commercialisation process of the technology will be conducted over two stages, the first focusing on generating consumer responses to the technology and the second for the product to incorporate these responses. Initial agreement will see OBJ bank upfront, standstill fees and royalties


The securities of OBJ Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement.


The suspension of trading in the securities of OBJ Limited (the "Company") will be lifted immediately, following the release by the Company of an announcement regarding results of the BodyGuard clinical trial. Security Code: OBJ


The company is pleased to report that The University of Queensland has completed its clinical trial examining the efficacy of OBJ's Bodyguard Kneeguard against the world's largest selling topical non-steroidal anti-inflammatory drug product with the company's primary objectives being successfully met.


The securities of OBJ Limited (the "Company") will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement. Security Code: OBJ


reinstatement to quotation


name changed from Objectif Telecommunications Limited



Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    09/10/2018Steven Schapera1,100,000$0.022$24,287
    07/08/2018Steven Schapera2,459,999$0.029$70,880
    15/05/2018Steven Schapera349,151$0.027$9,331
    09/05/2018Steven Schapera2,066,000$0.027$56,525
    14/10/2014Glyn Denison-395,045$0.106$41,795

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Antonio VaranoNon Exec Chairman15/05/2018
    Jeff EdwardsManaging Director07/10/2004
    Paul PerosCEO14/04/2020
    Steven SchaperaNon Exec Director01/08/2017
    Cameron ReynoldsNon Exec Director01/07/2018

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Christopher QuirkNon Exec Director19/11/200430/04/2020
    Glyn DenisonDirector22/02/200620/02/2018

    Date of first appointment, title may have changed.